🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨 Coming This Summer: A Phase 2/3 Clinical Trial of KPL-387 in #RecurrentPericarditis! 🚨 📅 Trial initiation expected mid-2025. 💉 KPL-387 is designed for once-monthly subcutaneous dosing in a liquid formulation. 🔬 Follow us to learn more about our #clinicaltrials.

Dr. DeLisa Fairweather—a leading researcher and member of the Myocarditis Foundation’s Medical Advisory Board—breaks down how biological sex influences immune responses, symptoms, and outcomes in myocarditis patients. myocarditisfoundation.org/research-and-g…

Excited to share this video of the UCSF Cardiology research and clinical efforts in cardio-oncology & cardio-immunology! #CardioOnc Myocarditis Fndn International Cardio-Oncology Society AHA Research Kiniksa Pharmaceuticals American Heart Association Nature Cardiovascular Research UCSF Health vimeo.com/1036624044

Big news! The Myocarditis Foundation is thrilled to welcome our second 2025 NYC Marathon runner—Pardis Khorasani. Pardis has committed to running, fundraising, and spreading awareness on behalf of the Myocarditis Foundation. We encourage everyone to show their support by donating

Happy Heart Fact Friday! We hope everyone had a great week and has an even better weekend!

New Research Update! A major new study co-authored by our co-founder Dr. Leslie Cooper and Medical Advisory Board member Dr. Enrico Ammirati confirms what we've long hoped: patients with uncomplicated myocarditis face a very low risk of serious events during hospitalization. This

New in The British Journal of Psychiatry: A multidisciplinary consensus on preventing, screening, and monitoring clozapine-associated myocarditis—plus guidance on rechallenging after myocarditis. This is a critical step toward safer psychiatric care and better outcomes for

The Myocarditis Foundation Co-Founder, Dr. Leslie Cooper, served as a co-author on a newly published international consensus that provides expert-backed guidelines to help reduce the risk of myocarditis a rare but serious side effect of clozapine, a vital medication for

The Myocarditis Foundation is thrilled to announce that we officially have our three runners for the 2025 New York City Marathon! Please join us in wishing the best of luck to Michael Conte, Pardis Khorasani, and Blake Guerrieri. Each of them is proudly running as a Myocarditis

Happy Heart Fact Friday! We hope everyone had a great week and has an even better weekend!

📢#ICYMI: We announced the Phase 2/3 trial design for KPL-387* in recurrent pericarditis at Jefferies Conf. 🧪Learn more: clinicaltrials.gov *KPL-387 is an investigational product. The safety and efficacy of KPL-387 have not been evaluated by any regulatory authority.

This article from the American Medical Association features insights from Dr. Lauren Weber on how to recognize the signs of myocarditis, when to seek medical attention, and why early diagnosis is critical. ama-assn.org/delivering-car…

The Myocarditis Foundation is proud to announce that we have added another pediatric cardiologist to our Board of Directors. Dr. Deipanjan Nandi, comes highly recommended to the Myocarditis Foundation, with much expertise in myocarditis. myocarditisfoundation.org/dr-deipanjan-n…

On Friday, May 30th, we had the pleasure of attending the Inflammatory Cardiac & Cardiovascular Disease Symposium at NYP Hospital, chaired by Dr. Dor Lotan, a member of the Myocarditis Foundation’s Board of Directors. We were thrilled to see so many attendees eager to learn more

We’re excited to shine a spotlight on one of our 2025 NYC Marathon runners, Michael Conte! Check out his page to learn what inspires him to run on behalf of the Myocarditis Foundation. Let’s rally behind him with our full support and help Michael reach—and even surpass—his

Happy Heart Fact Friday! We hope everyone had a great week and has an even better weekend!

Our hearts go out to the family of Bryson Funk, who tragically lost his life unexpectedly to myocarditis. Stories like his drive our mission to raise awareness about this disease and fund research grants to better understand it—with the hope of one day finding a cure and ways to

Excited to report this important collaboration which we hope helps us understand ICI-myocarditis better, published in #EHJ today! Along with the great DrJE-Salem! EHJ Editor-in-Chief Johann Bauersachs #CardioOnc UCSF Cardiology UCSF Helen Diller Family Comprehensive Cancer Ctr academic.oup.com/eurheartj/adva…

We additionally develop a risk score using these criteria which we hope helps clinicians across the globe!

Lots of new data to go through but here is one critical 1: we still have a long way to go in terms of treatment for patients. Despite some early (& flawed) data, corticosteroids do nothing (even at high doses) for patients...